Release Details

TARRYTOWN, N.Y.--(BUSINESS WIRE)--April 25, 2008--Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the Morgan Stanley Global Healthcare Unplugged Conference on Wednesday, April 30, 2008. The presentation will provide an overview of the Company and its clinical programs and is scheduled to be broadcast live on Wednesday, April 30 at 1:40 p.m. Eastern Time. The session may be accessed through the Company's web site (www.regeneron.com on the Investor Relations page, under the Presentations heading) at the time of the presentation. An archived version of the presentation will be available after the live webcast through May 30, 2008. Additional information about Regeneron and recent news releases are available on the Regeneron worldwide web site at www.regeneron.com

Regeneron is an integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST^™ (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates for the potential treatment of cancer, eye diseases, and inflammatory diseases and has preclinical programs in other diseases and disorders.

CONTACT: For Regeneron Pharmaceuticals, Inc.
Investor Relations, 914-345-7640
invest@regeneron.com
or
Laura Lindsay, 914-345-7800
Corporate Communications
Laura.lindsay@regeneron.com
or
Kimberly Chen, 212-845-5634
Media Relations
kchen@biosector2.com

SOURCE: Regeneron Pharmaceuticals, Inc.